Skip to main content

Permira To Acquire European Pharmaceutical Company Neuraxpharm

Private equity firm Permira is to acquire Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS) from funds advised by Apax Partners. Neuraxpharm develops and commercializes value-added medicines and consumer healthcare products for chronic patients suffering from neurological and psychiatric disorders including Epilepsy, Parkinson’s, Alzheimer’s, Depression and Psychosis.

Dr. Jörg Rockenhäuser, Head of DACH at Permira, said: “We are very excited to join forces with Neuraxpharm. The team led by CEO Dr. Jörg-Thomas Dierks has built one of the most relevant European players in the CNS field. With our longstanding global track-record in successfully transforming market leaders and our proven expertise in the healthcare sector, the Permira funds will back Neuraxpharm to reach the next level of growth. Our joint goal is to create the leading European CNS specialty platform with further acquisitions and strong organic growth. This transaction also marks an excellent start for our strengthened DACH healthcare team, led by Florian Kreuzer who joined Permira a year ago.”

Closing of the transaction is subject to customary closing conditions and is expected in the fourth quarter of 2020; financial details of the transaction were not disclosed.


© The Sortino Group Ltd

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.